Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747227 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)
A Phase 3 study of Cataract, sponsored by Abbott Medical Optics.
- Completed
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 11
- Study locations
NCT00747227 is a Phase 3 study of Cataract that has completed, run by Abbott Medical Optics. The registered enrollment target is 250 participants, above the 225-participant average among 83 other Cataract trials with a reported enrollment target (11% higher). The trial reports 11 study locations across 10 states.
The verdict
NCT00747227, a Phase 3 study of Cataract, has completed, sponsored by Abbott Medical Optics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of a new investigational modified light transmission monofocal intraocular lens compared to a conventional intraocular lens (IOL).
Conditions Studied
Interventions
- DEVICE modified light transmission intraocular lens
- DEVICE monofocal acrylic intraocular lens
Study Locations (11)
Pennsylvania
- William Christie, M.D. - Cranberry Township
- Mark Blecher, M.D. - Philadelphia
Arizona
- Patrick Aiello, M.D. - Scottsdale
Arkansas
- Randall E. Cole, M.D. - Rogers
Connecticut
- Aron Rose, M.D. - New Haven
Minnesota
- Y. Ralph Chu, M.D. - Bloomington
Missouri
- Steven Silverstein, M.D. - Kansas City
Oregon
- Jon-Marc Weston, M.D. - Roseburg
Rhode Island
- Robert L. Bahr, M.D. - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00747227
The ClinicalTrials.gov registry entry for NCT00747227 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 225-participant average among 83 other Cataract trials with a reported enrollment target (11% higher). The listed sponsor is Abbott Medical Optics, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 2 interventions - of which modified light transmission intraocular lens is the first listed.
NCT00747227 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Pennsylvania, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00747227 about?
NCT00747227 is a clinical study titled "Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)". The purpose of this study is to evaluate the safety and effectiveness of a new investigational modified light transmission monofocal intraocular lens compared to a conventional intraocular lens (IOL).
What is the current status of trial NCT00747227?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2006-12. Estimated completion is 2009-06.
What conditions does trial NCT00747227 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT00747227?
The interventions under investigation include: modified light transmission intraocular lens (DEVICE), monofocal acrylic intraocular lens (DEVICE).
Who is sponsoring clinical trial NCT00747227?
This trial is sponsored by Abbott Medical Optics, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00747227 being conducted?
This trial has 11 study locations across Arizona, Arkansas, Connecticut, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
COMPLETED · Phase 3
-
Study of T-PRED(TM) Compared to Pred Forte(R) II
COMPLETED · Phase 3
-
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.